Drug Trial Radar · NCT06679881
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
170
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Aug 19, 2031
Study completion Aug 19, 2031
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Conditions
- Hereditary Angioedema (HAE)
Interventions
DeucrictibantDrug
Deucrictibant extended-release tablet for once daily oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuationTime frame: Up to Week 240
- Change in heart rateTime frame: Up to Week 240
- Change in blood pressureTime frame: Up to Week 240
- Change in body temperatureTime frame: Up to Week 240
- Number of participants with clinically significant changes in HematologyTime frame: Up to Week 240
- Number of participants with clinically significant changes in Clinical ChemistryTime frame: Up to Week 240
- Number of participants with clinically significant changes in UrinalysisTime frame: Up to Week 240
- Change from Baseline electrocardiograms (ECGs)Time frame: Up to Week 240
Locations
67 sites in 23 countries. Site status is shown where the registry gives one.
Study Site
Birmingham, Alabama
Study Site
Scottsdale, Arizona
Study Site
Little Rock, Arkansas
Study Site
San Diego, California
Study Site
Santa Monica, California
Study Site
Walnut Creek, California
Study Site
Colorado Springs, Colorado
Study Site
Wheaton, Illinois
Study Site
St Louis, Missouri
Study Site
Las Vegas, Nevada
Study Site
Hershey, Pennsylvania
Study Site
Dallas, Texas
Study Site
Milwaukee, Wisconsin
Study Site
Corrientes, Argentina
Study Site
Pilar, Argentina
Study Site
Salta, Argentina
Study Site
Box Hill, Australia
Study Site
Parkville, Australia
Study Site
Perth, Australia
Study Site
Sydney, Australia
Study Site
Vienna, Austria
Study Site
Ribeirão Preto, Brazil
Study Site
Salvador, Brazil
Study Site
Santo André, Brazil
Study Site
São Paulo, Brazil
Study Site
São Paulo, Brazil
Study Site
Sofia, Bulgaria
Study Site
Edmonton, Canada
Study Site
Montreal, Canada
Study Site
Beijing, China
Study Site
Grenoble, France
Study Site
Berlin, Germany
Study Site
Frankfurt, Germany
Study Site
Munich, Germany
Study Site
Hong Kong, Hong Kong
Study Site
Budapest, Hungary
Study Site
Dublin, Ireland
Study Site
Milan, Italy
Study Site
Padova, Italy
Study Site
Palermo, Italy
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.